AIMS: The aim of this study was to investigate the prognosis in patients with atrial fibrillation (AF) and intracerebral haemorrhage (ICH) having a left atrial appendage occlusion (LAAO) versus patients receiving standard medical therapy. METHODS AND RESULTS: A total of 151 patients from the Nordic countries with AF and previous ICH who underwent LAAO using the AMPLATZER Cardiac Plug or the AMPLATZER AMULET were compared to a propensity score-matched group of 151 patients receiving standard medical therapy. The two groups were matched so that their risks for stroke and bleeding were similar (CHA2DS2-VASc and HAS-BLED scores). The standard care patients were identified from the Danish Stroke Registry among 787 patients with AF and ICH. The primary endpoint was a composite of all-cause mortality, ischaemic stroke and major bleeding. Patients with AF and a prior ICH treated with LAAO had a lower risk of the composite outcome as compared to patients treated with standard medical care (events/1,000 years [95% confidence interval]: 53.3 [44.3-64.1] vs. 366.7 [298.2-450.9]; hazard ratio 0.16 [0.07-0.37]). CONCLUSIONS: LAAO is suggested to be of major clinical benefit in AF patients having sustained an ICH. These results have to be confirmed in a randomised clinical trial.
AIMS: The aim of this study was to investigate the prognosis in patients with atrial fibrillation (AF) and intracerebral haemorrhage (ICH) having a left atrial appendage occlusion (LAAO) versus patients receiving standard medical therapy. METHODS AND RESULTS: A total of 151 patients from the Nordic countries with AF and previous ICH who underwent LAAO using the AMPLATZER Cardiac Plug or the AMPLATZER AMULET were compared to a propensity score-matched group of 151 patients receiving standard medical therapy. The two groups were matched so that their risks for stroke and bleeding were similar (CHA2DS2-VASc and HAS-BLED scores). The standard care patients were identified from the Danish Stroke Registry among 787 patients with AF and ICH. The primary endpoint was a composite of all-cause mortality, ischaemic stroke and major bleeding. Patients with AF and a prior ICH treated with LAAO had a lower risk of the composite outcome as compared to patients treated with standard medical care (events/1,000 years [95% confidence interval]: 53.3 [44.3-64.1] vs. 366.7 [298.2-450.9]; hazard ratio 0.16 [0.07-0.37]). CONCLUSIONS:LAAO is suggested to be of major clinical benefit in AFpatients having sustained an ICH. These results have to be confirmed in a randomised clinical trial.
Authors: Tatiana Busu; Safi U Khan; Muhammad Alhajji; Fahad Alqahtani; David R Holmes; Mohamad Alkhouli Journal: Am J Cardiol Date: 2020-03-14 Impact factor: 2.778
Authors: Mohammed Osman; Tatiana Busu; Khansa Osman; Safi U Khan; Matthew Daniels; David R Holmes; Mohamad Alkhouli Journal: JACC Clin Electrophysiol Date: 2020-01-29
Authors: Roberto Galea; Federico De Marco; Adel Aminian; Nicolas Meneveau; Frederic Anselme; Christoph Gräni; Adrian T Huber; Emmanuel Teiger; Xavier Iriart; Marco Angelillis; Nicolas Brugger; Alessandro Spirito; Noé Corpataux; Anna Franzone; Pascal Vranckx; Urs Fischer; Giovanni Pedrazzini; Francesco Bedogni; Stephan Windecker; Lorenz Räber; Marco Valgimigli Journal: J Cardiovasc Transl Res Date: 2021-04-21 Impact factor: 4.132
Authors: Michael Gotzmann; Dinah S Choudhury; Maximilian Hogeweg; Florian Heringhaus; Andreas Mügge; Andreas Pflaumbaum Journal: Clin Cardiol Date: 2020-01-22 Impact factor: 2.882